IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A

Flora Peyvandi, Syna Miri, Paolo Bucciarelli, Carla Valsecchi, Lucia Schiavone, Marco Boscarino, Roberta Palla, Pier Mannuccio Mannucci, F. R. Rosendaal, the SIPPET group

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated longitudinally the behaviour of anti-factor VIII (anti-FVIII) IgG subclasses for 6 months from inhibitor development in 43 patients from the Survey of Inhibitors in Plasma-Products Exposed Toddlers (SIPPET) trial who developed persistent or transient inhibitors. We first analysed 43 patients within 60 days post inhibitor detection. Then, 14 of these 43 patients were studied at five time points over 6 months. Our study showed that during the first 60 days, the risk of inhibitor persistence increased with the concomitant presence of an increasing number of IgG subclasses. Over the 6-month period post inhibitor detection, only the IgG2 subclass could be considered a hallmark of inhibitor persistence.

Original languageEnglish
Pages (from-to)621-625
Number of pages5
JournalBritish Journal of Haematology
Volume192
Issue number3
DOIs
Publication statusPublished - Feb 2021

Keywords

  • haemophilia A
  • IgG subclasses
  • inhibitor
  • predictive biomarkers

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A'. Together they form a unique fingerprint.

Cite this